权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Diversification of Glomerular Kidney Disease Treatments By Targeting Therapeutics to the Kidney

通过针对肾脏的治疗来实现肾小球肾病治疗的多样化

基本信息

批准号：
10808617
负责人：
MELANIE S JOY
金额：
$ 36.79万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2025-09-14
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10808617
关键词：
Acute Animal Model Annexins Biodistribution Characteristics Charge Chronic Colorado Deposition Development Dialysis procedure Disease Dose Drug Delivery Systems Drug Formulations Drug Kinetics End stage renal failure Exhibits Exposure to Formulation Glomerular Mesangial Cell Grant Growth Factor Receptors Human Imatinib Immunoglobulin Fragments Immunosuppression In Vitro Kidney Kidney Diseases Ligands Link Localized Disease Lupus Lupus Nephritis Medical center Morbidity - disease rate Mus Oils PDGFRB gene Particle Size Pathology Patients Pharmaceutical Preparations Pharmacodynamics Platelet-Derived Growth Factor Platelet-Derived Growth Factor Receptor Population Process Proteins Publishing Renal function Renal glomerular disease Research Risk Safety Schools Scientist Structure Survival Rate Systemic Lupus Erythematosus Techniques Testing Therapeutic Toxic effect Toxicology Translating Treatment Efficacy Universities Water clinical efficacy drug development effective therapy efficacy evaluation improved in vivo mesangial cell mortality mortality risk mouse model nanoemulsion nanoformulation novel novel strategies pre-clinical receptor side effect synergism systemic toxicity targeted treatment treatment response uptake

项目摘要

ABSTRACT Novel approaches to the treatment of glomerular kidney diseases are needed given that they represent the third most common cause of end stage renal disease. Systemic lupus erythematosus induced kidney disease (SLEN) is one glomerular disease where up to 60% of patients exhibit significant declines in kidney function, resulting in end stage renal disease in ~20%. Although novel treatments are being explored for lupus, they generally do not benefit the majority of patients and cause systemic immunosuppression, leaving the majority of the population with less effective treatment options. Additionally, neither new nor old treatments have been evaluated for their ability to target to the kidney and achieve sufficient exposure to influence the localized disease processes. The development of novel and effective renal targeted treatment approaches for glomerular kidney diseases, including SLEN, are needed to meet the clinical efficacy and safety needs of patients with these disorders. We have recently published research for enhanced kidney deposition of imatinib in a murine model of SLEN, when formulated in a nanoemulsion developed to optimize kidney exposure. Results from our studies showed three-fold higher kidney deposition of imatinib in MRL/MpJ-Faslpr mice that received our novel nanoformulation vs. free drug. We will now test the novel imatinib formulation after chronic dosing to evaluate efficacy and safety in two mouse models of SLEN. We will also modify this formulation by linking a relevant ligand or an antibody fragment to target a receptor and protein, respectively, that are upregulated in glomerular mesangial cells in SLEN. We will test whether these formulation techniques applied to the existing nanoemulsion will enhance imatinib glomerular deposition and retention, improve selectivity for targeting mesangial cells, improve therapeutic efficacy and provide relative safety, as compared to our primary formulation. The central hypotheses of our research are that 1) promising SLEN treatments can be formulated to enhance delivery to the diseased kidney and targeted structures, and 2) animal models that represent human SLEN will demonstrate favorable treatment responses, pharmacokinetics, and enhanced safety with imatinib nanoformulations vs. free drug. The research team comprised of scientists with diverse backgrounds in glomerular kidney diseases, drug development, nanoformulations, toxicology, and renal pathology across schools at the University of Colorado Anschutz Medical Center, will synergize their efforts to successfully develop novel strategies to enhance kidney delivery and accumulation of therapeutics for the treatment of glomerular kidney diseases.

摘要